Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: The international society of geriatric oncology (SIOG) task force

Annals of Oncology

Volumn 25, Issue 11, 2014, Pages 2134-2146

  Kunkler, I H ^a   Audisio, R ^b   Belkacemi, Y ^c   Betz, M ^d   Gore, E ^e   Hoffe, S ^f   Kirova, Y ^g   Koper, P ^h   Lagrange, J L ^c   Markouizou, A ⁱ   Pfeffer, R ^j   Villa, S ^k  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c HENRI MONDOR HOSPITAL   (France)

^d Hirslanden Lausanne   (Switzerland)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g INSTITUT CURIE   (France)

^h Radiotherapy Center West   (Netherlands)

ⁱ METAXA CANCER HOSPITAL   (Greece)

^j ASSUTA MEDICAL CENTER   (Israel)

^k CATALAN INSTITUTE OF ONCOLOGY   (Spain)

more..

Author keywords

Adjuvant; Elderly; Radiotherapy

Indexed keywords

AGE; ARTICLE; BRACHYTHERAPY; BREAST CANCER; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; COMPUTER ASSISTED RADIOTHERAPY; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; EXTERNAL BEAM RADIOTHERAPY; GERIATRIC ASSESSMENT; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG CANCER; MEDICAL PRACTICE; NEOPLASM; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PATIENT SAFETY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; RESEARCH PRIORITY; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT PLANNING; AGED; CONFORMAL RADIOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PATHOLOGY; RADIOSURGERY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; RADIOSURGERY; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84918812572     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu104     Document Type: Article

References (91)

1. Lamont DW, Gillis CR, Caird FI. Epidemiology of cancer. In Caird FI, Brewin TB, eds. Cancer in the Elderly, Wright, Butterworth & Co., 1990: 9-15.
2. Delaney GP, Jacob S, Featherstone C et al. Collaboration for Cancer Outcomes Research and Evaluation (CCORE), Liverpool Hospital, Sydney. Radiotherapy in Cancer Care: estimating optimal utilisation from a review of the evidence-based clinical Guidelines. 2003. http://www.canceraustralia.gov.au.
3. Firat S, Pleister A, Byhardt RW et al. Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC). Am J Clin Oncol 2006; 29: 252-257.
4. Mor V, Masterson-Allen S, Goldberg RJ et al. Relationship between age at diagnosis and treatment received by cancer patients. J Am Geriatr Soc 1985; 33: 585-589.
5. Samet J, Hunt WC, Key C et al. Choice of cancer therapy varies with age of patient. JAMA 1986; 255: 3385-3390.
6. Ten Haken RK, Lawrence TS. The clinical application of intensity-modulated radiation therapy. Semin Radiat Oncol 2006; 16: 224-231.
7. Wu VW, Law MY, Star-Lack J et al. Technologies of image guidance and the development of advanced linear accelerator systems for radiotherapy. Front Radiat Ther Oncol 2011; 43: 132-164.
8. Swaminath A, Dawson LA. Emerging role of radiotherapy in the management of liver metastases. Cancer J 2010; 16: 150-155.
9. Chang BK, Timmerman RD. Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol 2007; 30: 637-644.
10. Li XA, Liu F, Tai A et al. Development of an online adaptive solution to account for inter- and intra-fractional variations. Radiother Oncol 2011; 100: 370-374.
11. Ahn PH, Chen CC, Ahn AI et al. Adaptive planning in intensity-modulated radiation therapy for head and neck cancers: single-institution experience and clinical implications. Int J Radiat Oncol Biol Phys 2011; 80: 677-685.
12. Schwartz DL, Garden AS, Shah SJ et al. Adaptive radiotherapy for head and neck cancer-dosimetric results from a prospective clinical trial. Radiother Oncol 2013; 106: 80-84.
13. Ahunbay E, Peng C, Holmes S et al. Online adaptive replanning method for prostate radiotherapy. Int J Radiat Oncol Biol Phys 2010; 77: 1561-1572.
14. Early Breast Cancer Trialists' Collaborative Group (EBCTCG)Darby S, McGale P, Correa C et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data on 10,801 women in 17 randomised trials. Lancet 2011; 378: 1707-1716.
15. Hughes KS, Schnaper LA, Berry D et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Eng J Med 2004; 351: 971-977.
16. Hughes KS, Schnaper LA, Bellon JR et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: longterm follow-up of CALGB 9343. J Clin Oncol 2013; 31: 2382-2387.
17. START Trialists' GroupBentzen SM, Agrawal RK, Aird EG et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008; 371: 1098-1107.
18. Haviland JS, Agrawal R, Aird E et al. The UK START (Standardisation of Breast Radiotherapy) trials: 10-year follow-up results. Cancer Res 2012; 72: S3.
19. Whelan TJ, Pignol JP, Levine MN et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362: 513-520.
20. Vaidya JS, Joseph DJ, Tobias JS et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010; 376: 91-102.
21. Vaidya JS, Wenz F, Bulsara M et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 2014; 383: 603-613.
22. Veronesi U, Orecchia R, Maisonneuve P et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 2013; 14: 1269-1277.
23. Smith BD, Haffty BG, Hurria A et al. Postmastectomy radiation and survival in older women with breast cancer. J Clin Oncol 2006; 24: 4901-4907.
24. Kunkler IH, Canney P, van Tienhoven G et al. MRC/EORTC (BIG 2-04) SUPREMO Trial Management Group. Elucidating the role of chest wall irradiation in 'intermediate-risk' breast cancer: the MRC/EORTC SUPREMO Trial. Clin Oncol 2008; 20: 31-34.
25. Kirova YM, Campana F, Savignoni A et al. Institut Curie Breast Cancer Study Group. Breast-conserving treatment in the elderly: long-term results of adjuvant hypofractionated and normofractionated radiotherapy. Int J Radiat Oncol Biol Phys 2009; 75: 76-81.
26. Grann A, McCormick B, Chabner ES et al. Prone breast radiotherapy in early-stage breast cancer: a preliminary analysis. Int J Radiat Oncol Biol Phys 2000; 47: 319-325.
27. Owonikoko TK, Ragin CC, Belani CP et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007; 25: 5570-5577.
28. Yu HM, Liu YF, Yu JM et al. Involved-field radiotherapy is effective for patients 70 years old or more with early stage non-small cell lung cancer. Radiother Oncol 2008; 87: 29-34.
29. Haasbeek CJ, Lagerwaard FJ, Antonisse ME et al. Stage I nonsmall cell lung cancer in patients aged > or =75 years: outcomes after stereotactic radiotherapy. Cancer 2010; 116: 406-414.
30. Schild SE, Mandrekar SJ, Jatoi A et al. North Central Cancer Treatment Group. The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer 2007; 110: 363-368.
31. Weinmann M, Jeremic B, Bamberg M et al. Treatment of lung cancer in elderly part II: small cell lung cancer. Lung Cancer 2003; 40: 1-16.
32. Bayman N, Alam N, Faivre-Finn C. Radiotherapy for lung cancer in the elderly. Lung Cancer 2010; 68: 129-136.
33. Aupérin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999; 341: 476-484.
34. Thieblemont C, Grossoeuvre A, Houot R et al. Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 2008; 19: 774-779.
35. Spicer J, Smith P, Maclennan K et al. Long-term follow- up of patients treated with radiotherapy alone for early-stage histologically aggressive non-Hodgkin's lymphoma. Br J Cancer 2004; 90: 1151-1155.
36. Miller TP, Dahlberg S, Cassady JR et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non- Hodgkins lymphoma. N Engl J Med 1998; 339: 21-26.
37. Bonnet C, Fillet G, Mounier N et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007; 25: 787-792.
38. Diepstra A, van Imhoff GW, Schaapveld M et al. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol 2009; 27: 3815-3821.
39. Engert A, Plütschow A, Eich HT et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363: 640-652.
40. Klimm B, Eich HT, Haverkamp H et al. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol 2007; 18: 357-363.
41. Engert A, Ballova V, Haverkamp H et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 2005; 23: 5052-5060.
42. Daskivich TJ, Chamie K, Kwan L et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 2011; 117: 2058-2066.
43. Nguyen PL, Chen MH, Beard CJ et al. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys 2010; 77: 1046-1052.
44. Jones CU, Hunt D, McGowan DG et al. Radiotherapy and short-term deprivation for localized prostate cancer. N Engl J Med 2011; 365: 107-118.
45. Denham JW, Steigler A, Lamb DS et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011; 12: 451-459.
46. McGowan D, Hunt D, Jones C et al. Effects of short-term endocrine therapy prior to and during radiation therapy on overall survival in patients with T1b-T2b adenocarcinoma of the prostate and PSA equal to or less than 20: initial results of RTOG 94-08. Genitourinary Cancers Symposium (GUCS), San Francisco 2010. Abstract 6, 30653-30673.
47. Bolla M, de Reijke TM, Van Tienhoven GV et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-2527.
48. D'Amico AV, Chen MH, Renshaw AA et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008; 299: 289-295.
49. Tyrrell CJ, Payne H, See WA et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol 2005; 76: 4-10.
50. Dearnaley DP, Khoo VS, Norman AR et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999; 353: 267-272.
51. Arcangeli G, Fowler J, Gomellini S et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011; 79: 1013-1021.
52. Roberts CB, Albertsen PC, Shao YH et al. Patterns and correlates of prostate cancer treatment in older men. Am J Med 2011; 124: 235-243.
53. Soubeyran P, Bellera C, Goyard J et al. Validation of the G8 screening tool in geriatric oncology: the ONCODAGE project. J Clin Oncol 2011; 29: 9001.
54. Keys HM, Roberts JA, Brunetto VL et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 744-751.
55. Scholten AN, van Putten WL, Beerman H et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005; 63: 834-838.
56. Creutzberg CL, Nout RA, Lybeert ML et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 2011; 81: e631-e638.
57. Nout RA, Creutzberg CL. Point: vaginal brachytherapy should be a standard adjuvant treatment for intermediate-risk endometrial cancer. Brachytherapy 2011; 10: 1-3.
58. Creutzberg CL, Nout RA. The role of radiotherapy in endometrial cancer: current evidence and trends. Curr Oncol Rep 2011; 13: 472-478.
59. Nout RA, Putter H, Jurgenliemk-Schulz IM et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer 2012; 48: 1638-1648.
60. Kong A, Johnson N, Kitchener HC et al. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev 2012; 4: CD003916.
61. Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer (PORTEC-3). ClinicalTrials.gov identifier: NCT00411138.
62. Chuong MD, Springett GM, Freilich JM et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys 2013; 86: 516-522.
63. Kim CH, Ling DC, Wegner RE et al. Stereotactic body radiotherapy in the treatment of pancreatic adenocarcinoma in elderly patients. Radiat Oncol 2013; 8: 240.
64. Horowitz DP, Hsu CC, Wang J et al. Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2011; 80: 1391-1397.
65. Lin SH, Wang L, Myles B et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2012; 84: 1078-1085.
66. Shridhar R, Chuong MD, Weber J et al. Outcomes of definitive or preoperative IMRT chemoradiation for esophageal cancer. J Radiat Oncol 2012; 1: 347-354.
67. Chen YJ, Liu A, Han C et al. Helical tomotherapy for radiotherapy in esophageal cancer: a preferred plan with better conformal target coverage and more homogeneous dose distribution. Med Dosim 2007; 32: 166-171.
68. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264: 1444-1450.
69. Sauer R, Becker H, Hohenberger W et al.; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740.
70. Mantello G, Berardi R, Cardinali M et al. Feasibility of preoperative chemoradiation in rectal cancer patients aged 70 and older. J Exp Clin Cancer Res 2005; 24: 541-546.
71. Maas HA, Lemmens VE, Nijhuis PH et al. Benefits and drawbacks of short-course preoperative radiotherapy in rectal cancer patients aged 75 years and older. Eur J Surg Oncol 2013; 39: 1087-1093.
72. Rutten HJ, den Dulk M, Lemmens VE et al. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol 2008; 9: 494-501.
73. Papillon J, Berard P. Endocavitary irradiation in the conservative treatment of adenocarcinoma of the low rectum. World J Surg 1992; 16: 451-457.
74. Habr-Gama A, Perez RO, Nadalin W et al. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg 2005; 9: 90-99.
75. Lo SS, Moffatt-Bruce SD, Dawson LA et al. The role of local therapy in the management of lung and liver oligometastases. Nat Rev Clin Oncol 2011; 8: 405-416.
76. Curran WJ, Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85: 704-710.
77. Lutterbach J, Bartelt S, Momm F et al. Is older age associated with a worse rognosis due to different patterns of care? A long-term study of 1346 patients with glioblastomas or brain metastases. Cancer 2005; 103: 1234-1244.
78. Christensen BC, Smith AA, Zheng S et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst 2011; 103: 143-153.
79. Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007; 356: 1527-1535.
80. Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004; 22: 1583-1588.
81. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
82. Brandes AA, Franceschi E, Tosoni A et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 2009; 115: 3512-3518.
83. Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012; 13: 707-715.
84. Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012; 13: 916-926.
85. Noel G, Bollet MA, Noel S et al. Linac stereotactic radiosurgery: an effective and safe treatment for elderly patients with brain metastases. Int J Radiat Oncol Biol Phys 2005; 63: 1555-1561.
86. Kocher M, Soffietti R, Abacioglu U et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011; 29: 134-141.
87. Grénman R, Chevalier D, Gregoire V et al. Treatment of head and neck cancer in the elderly: European Consensus (panel 6) at the EUFOS Congress in Vienna 2007. Eur Arch Otorhinolarygnol 2010; 267: 1619-1621.
88. Huang SH, O'Sullivan B, Waldron J et al. Patterns of care in elderly head-and-neck cancer radiation oncology patients: a single-center cohort study. Int J Radiat Oncol Biol Phys 2011; 79: 46-51.
89. Pignon JP, Le Maître A, Maillard E et al. MACH-NC Collaborative Group. Metaanalysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
90. Nutting CM, Morden JP, Harrington KJ et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011; 12: 127-136.
91. Rosenthal DI, Fuller CD, Barker JL, Jr et al. Simple carotid-sparing intensitymodulated radiotherapy technique and preliminary experience for T1-2 glottic cancer. Int J Radiat Oncol Biol Phys 2010; 77: 455-461.